REQUIP Is Effective Adjunct Therapy When Combined with L-dopa

REQUIP can be added to L-dopa therapy in patients with idiopathic Parkinson's disease. This can lead to improved symptom control and decreased "wearing-off" in patients with Parkinson’s disease.⁸ Using REQUIP allows a reduction in L-dopa dose while maintaining symptom control.⁸

Adding REQUIP reduced L-dopa dose by 191 mg more than placebo (-242 mg/day [n=95] vs -51 mg/day [n=54], P<0.001)⁸

May help reduce or spare the need for additional L-dopa. ⁸

Adjunct therapy with REQUIP may reduce the need to add further L-dopa⁸
REQUIP as an adjunct to L-dopa allows for a gradual decrease in the concurrent L-dopa dose⁸

*Mean daily dose of L-dopa at baseline: 759 ± 422 mg (REQUIP + L-dopa) and 843 ± 517 mg (placebo + L-dopa).
†Includes those patients with reductions due to adverse events.
‡Data from a 6-month, double-blind, multicenter, randomized, placebo-controlled trial of REQUIP as adjunct therapy with supplemental L-dopa in patients with PD (Hoehn & Yahr stage II-IV at baseline). The primary end point was a > 20% reduction in awake time spent
"off " and a > 20% reduction in total daily L-dopa dose between baseline and final visits.

Improve patients’ motor fluctuations with REQUIP as an adjunct to L-dopa. Adjunct therapy with REQUIP decreases "off" time.⁸

Adjunct therapy with REQUIP

Significantly reduces awake time spent "off"⁸
Helps reduce or spare the need for additional L-dopa⁸

§Data from a 6-month, double-blind, multicenter, randomized, placebo-controlled trial of REQUIP as adjunct therapy with supplemental L-dopa in patients with Parkinson’s disease (Hoehn & Yahr stage II-IV at baseline). The primary end point was a >20% reduction in awake time spent "off " and a >20% reduction in total daily L-dopa dose between baseline and final visits. Excludes patients with reductions in L-dopa dose due to adverse events and excludes 1 ropinirole patient from the primary efficacy analysis.